{
    "2021-10-01": [
        [
            {
                "time": "2023-10-05",
                "original_text": "Eli Lilly's Mirikizumab Maintains Symptomatic Remission for Two Years In Ulcerative Colitis Patients",
                "features": {
                    "keywords": [
                        "Mirikizumab",
                        "symptomatic remission",
                        "ulcerative colitis",
                        "two years"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Pharma Stock Roundup: MRK to Buy XLRN, ABBV Gets FDA Nod for Migraine Drug & More",
                "features": {
                    "keywords": [
                        "MRK",
                        "XLRN",
                        "ABBV",
                        "FDA nod",
                        "migraine drug"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "At Week 104, 75% of Patients with Ulcerative Colitis Taking Mirikizumab Maintained Symptomatic Remission in Phase 2 Study",
                "features": {
                    "keywords": [
                        "week 104",
                        "75%",
                        "ulcerative colitis",
                        "Mirikizumab",
                        "symptomatic remission",
                        "phase 2 study"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "The Zacks Analyst Blog Highlights: Eli Lilly, Costco, Applied Materials, Illumina and Norfolk Southern Corp",
                "features": {
                    "keywords": [
                        "Zacks Analyst Blog",
                        "Eli Lilly",
                        "Costco",
                        "Applied Materials",
                        "Illumina",
                        "Norfolk Southern Corp"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "retail",
                        "technology",
                        "transportation"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}